Fevertree Drinks PLC

Overview

This is a Magic Formula–style quantitative and qualitative analysis of Fevertree Drinks PLC (LSE:FEVR). It evaluates the business through Joel Greenblatt's two core lenses: earnings yield (EBIT / enterprise value) as the cheapness test and return on capital (EBIT / invested capital) as the quality test. The report then assesses whether the stock would likely rank well in a systematic Magic Formula screen.

Business Quality Assessment

Fevertree is a high-quality branded consumer business. It has leading premium mixer market positions in the UK, Europe and the US, with around 45% of revenue now coming from beyond tonic, particularly ginger beer and premium adult soft drinks. The business is asset-light and outsources production, which supports exceptional returns on tangible capital. Based on FY25 data, tangible invested capital is roughly £72m (inventory £37.1m + receivables £79.3m - payables £53.7m - provisions £2.8m + net PP&E £11.7m). Using pre-exceptional EBIT of £29.7m, return on tangible capital is approximately 41%. Even if acquired intangibles of £61.5m are included, return on capital is still around 22–24%. Historically the company has generated high returns because its competitive advantage comes from brand equity, pricing power and route-to-market scale rather than heavy fixed assets. However, 2025 returns are pressured by the US Molson Coors transition, a 16% drop in adjusted EBITDA, lower UK on-trade demand and a disputed EPR packaging levy. The underlying quality is intact, but current reported profitability does not fully reflect the historical earnings power of the core brand.

Valuation Analysis

On a Magic Formula earnings yield basis, Fevertree is not statistically cheap. Enterprise value is approximately £814m: market cap £901.4m + £3.6m lease liabilities - £91.1m cash. FY25 pre-exceptional EBIT was £29.7m, giving an earnings yield of only about 3.6%. If the £2.8m EPR provision is added back, normalized EBIT rises to roughly £32.5m, lifting the earnings yield to about 4.0%. Even using 2026 market expectations for around £50m EBITDA and adjusting for depreciation and amortisation still leaves an earnings yield below 5%. That is low compared with a typical Magic Formula screen, where attractive names often show double-digit EBIT/EV. The trailing P/E of 42.8 and forward P/E of 20.9 confirm that the market is already paying a premium for future recovery. This is a high-quality compounder, but the entry price does not satisfy the 'buy cheap' half of Greenblatt's discipline.

Magic Formula Ranking

Normalized Earnings Analysis

Reported FY25 earnings understate underlying profitability. Adjusted EBITDA of £42.4m included a £2.8m EPR provision related to a disputed packaging levy, and the company booked £5.2m of exceptional costs from the Molson Coors US transition. Adjusting for those items suggests normalized EBIT closer to £32–35m. Company-reported normalized EPS was 24.12p, down from 28.01p but above statutory EPS of 18.78p. However, even after normalization, the stock trades at roughly 30–34x normalized earnings and only about 4% EBIT/EV. The US partnership improves capital intensity but also changes the profit structure toward royalty-like economics, so some margin reset is permanent rather than one-off. Sustainable owner earnings are perhaps £25–32m after tax, not enough to make the current £901m market cap look cheap under Magic Formula standards.

Why The Market Is Wrong

The market may be overly focused on backward-looking statutory revenue and earnings declines caused by the US accounting change. Underlying Fever-Tree brand revenue grew 4% at constant currency in FY25, the US grew 6%, and the brand gained share despite the transition to Molson Coors. The beyond-tonic portfolio is diversifying the business, and management has extended buybacks and reaffirmed 2026 guidance. The contrarian case is that current earnings are temporarily depressed and the Molson Coors partnership will produce accelerating US growth and margin recovery. That said, this is not a situation where the market is clearly wrong about valuation. The shares already embed a meaningful recovery, with a forward P/E above 20 and an EV/EBITDA around 19x adjusted FY25 EBITDA. For a Magic Formula investor, the prudent conclusion is that the quality story is real but the price is not offering enough margin of safety.

Key Risks

Conclusion

Fevertree is exactly the kind of good business Magic Formula investors want to own: strong brand, asset-light model, high return on tangible capital, net cash and shareholder-friendly capital returns. However, the stock is not cheap on normalized EBIT/EV, with an earnings yield of only about 4%. Greenblatt's system would favour patience and price discipline. Existing holders can reasonably hold given the quality and recovery optionality, but this does not qualify as a high-conviction Magic Formula buy at 814p. A better entry would require a significantly lower price or clear evidence that normalized EBIT is inflecting sharply higher.

Overview

This is a CAN SLIM-style investment analysis of Fevertree Drinks PLC (LSE:FEVR) as of 2026-09-08. It applies William J. O'Neil's methodology from How to Make Money in Stocks, focusing on current and annual earnings, new products/catalysts, supply/demand, relative leadership, institutional sponsorship and market direction. The report uses structured financial data alongside recent company announcements and news flow.

Financial and Business Overview

Fevertree Drinks is a premium mixer and adult soft drinks company, best known for tonic water but increasingly diversified into ginger beer, sodas, cocktail mixers and non-alcoholic ready-to-drink formats. FY25 reported a strategic US transition under the Molson Coors partnership. Adjusted revenue was £375.3m, up 3% at constant currency, while statutory revenue fell 12% to £325.0m due to the new US royalty-style accounting treatment. Adjusted EBITDA fell 16% to £42.4m, and diluted EPS declined 11% to 18.62p. Net income was £22.6m. The balance sheet remains debt-free with cash of £91.1m. Market capitalisation is about £901m. Trailing P/E is 42.8, forward P/E is 20.9. Reference data show TTM EPS of 19p, a current-year estimate of 29p and a forward estimate of 39p, implying a sharp expected earnings rebound in 2026/2027, though these are forecasts rather than reported results.

Market Position & Competitive Advantages

Fevertree is the world's leading premium carbonated mixer brand by retail value. It has strong brand equity, premium pricing power and category leadership in tonic and ginger beer. The Molson Coors partnership gives access to roughly 400 US distributors and significant scale in the company's largest growth market. Products beyond tonic now represent about 45% of group revenue, reducing dependence on the mature UK tonic segment. The business is asset-light and cash-generative, with extended cost hedging for glass, energy and other inputs. Key competitive risks include supermarket private label, Schweppes and other premium mixers, plus structural weakness in UK on-trade and gin consumption. The US transition also means Fevertree now relies on Molson Coors for distribution, marketing and eventually production.

Stock Performance

As of 2026-09-08, the stock trades at 814p, up only about 5.1% over the past year. It is 16.3% below its 52-week high of 973p and 14.5% above the 52-week low of 711p. The shares sit below the 50-day moving average of 831.52p and the 200-day moving average of 833.35p. Average daily volume over 10 days is about 250,842 shares, below the three-month average of 375,729, indicating no strong accumulation surge. The company has been actively buying back and cancelling shares, which is a positive supply factor, but price and volume have not yet confirmed institutional accumulation.

CAN SLIM Analysis

Key Risks

Conclusion

Fevertree has a strong brand, a transformational US partnership, meaningful product diversification, a debt-free balance sheet and aggressive share buybacks. Those are real strengths. However, CAN SLIM is a growth and momentum methodology, and this stock currently fails several core elements. Reported annual EPS declined in FY25, there is no clean five-year annual earnings growth record, and the stock is below its 50-day and 200-day moving averages, well off its 52-week high. The N and S factors are positive, and institutional sponsorship is improving, but the lack of confirmed earnings acceleration and weak relative strength argue against buying before the 10 September 2026 interim results. A strict CAN SLIM investor would wait for actual current-quarter earnings acceleration, improving annual earnings, and a high-volume breakout above resistance before initiating a new position. For existing holders, the stock is a hold with close risk management rather than a fresh buy.

Overview

A Druckenmiller-style macro, reflexivity, and opportunistic positioning analysis of Fevertree Drinks PLC (LSE:FEVR) as of 8 Sep 2026, evaluating the stock ahead of its 10 Sep 2026 interim results. The report focuses on the US Molson Coors partnership transition, UK/Europe on-trade weakness, buyback-led capital returns, and the asymmetry between a quality brand and a still-unproven earnings inflection.

Macro Context

The late-2026 macro backdrop is characterised by elevated geopolitical uncertainty (Middle East conflict, oil price spikes, US tariff volatility) and uneven consumer confidence. UK and European on-trade channels remain soft, pressured by labour costs, duties, and cautious discretionary spending. Central banks are not in a clear easing cycle despite growth concerns because energy-driven inflation remains a live tail risk. Secular trends still favour Fevertree: premiumisation, alcohol moderation, longer/lighter serves, and growth in adult premium soft drinks. Policy shifts include the UK Extended Producer Responsibility packaging levy and US tariffs on UK-produced goods until local US production is scaled.

Company Position in Macro Landscape

FEVR is a premium mixer and adult soft drink brand benefiting from the long-term premiumisation/moderation theme, with 45% of revenue now outside tonic and market-leading positions in premium mixers and global ginger beer. The Molson Coors partnership is a structural shift from consolidating US sales to a capital-light royalty/profit-share model; this depresses near-term reported revenue and margins but gives access to roughly 400 distributors and significantly higher US marketing. FY25 adjusted EBITDA fell 16% to £42.4m at an 11.3% margin, while underlying Fever-Tree brand sales grew 4% at constant currency. The company is a beneficiary of premiumisation but still exposed to weak UK on-trade traffic and the transition costs of its largest growth market.

Reflexivity Analysis

Positive feedback loops are present: buybacks reduce share count, support EPS and signal confidence; a successful Molson Coors distribution ramp can improve US growth and profitability, attracting momentum and institutional money; and better margin delivery could force a re-rating from a depressed trailing base. Negative reflexivity is also active: Lindsell Train selling creates a supply overhang; a 42.8x trailing P/E on depressed EPS makes the stock look expensive to value screens, reinforcing skepticism until earnings visibly inflect. Current price of 814p is below the 50-day average of 831.5p and 200-day average of 833.4p, and below the company's late-August buyback range of roughly 851-858p. That means the buyback is not yet providing strong reflexive support, but continued repurchases could stabilise the downside.

Competitive Position & Disruptive Threats

FEVR has strong brand equity, premium pricing power, and a broadening portfolio including ginger beer, sodas, cocktail mixers, and non-alcoholic RTDs. The Molson Coors partnership provides US distribution scale and execution capability well beyond the prior footprint. Key competitive threats include private-label mixers squeezing grocery shelf economics, Schweppes/Q Mixers/Fentimans in premium and craft segments, and substitution from RTD cocktails and hard seltzers. The moat is built on brand, taste, and distribution rather than proprietary technology, requiring continued marketing spend and innovation to defend share.

Asymmetric Risk/Reward

At 814p, market cap is about £901m with net cash of roughly £91m, giving an EV near £810m. Against FY25 adjusted EBITDA of £42.4m, that is about 19x historic EV/EBITDA; on 2026-27 recovery estimates of roughly £50-55m EBITDA, the multiple is a less demanding 15-16x. Downside to the 52-week low of 711p is about 12.7%, while upside to the 52-week high of 973p is about 19.5%—moderate asymmetry at best. Optionality exists through guaranteed US profit contributions from 2026-2030, margin improvement from US production onshoring, a possible £2.8m EPR provision reversal, and ongoing buybacks. Entry below the company's own recent buyback levels is mildly attractive, but not yet a high-conviction asymmetric setup.

Key Risks

Investment Details

Overview

A Peter Lynch-style analysis of Fevertree Drinks plc (FEVR.L), the premium mixer and adult soft drinks company, using FY25 results, the 2026 AGM update, share buyback announcements, and market data as of 2026-09-08, when the share price was 814p and the market cap was about £901m.

The Two-Minute Story

Fever-Tree is the premium mixer people see in supermarkets, bars, and airports. It made its name on tonic, but now about 45% of sales come from ginger beer, sodas, and adult soft drinks. The US business has been handed to Molson Coors for distribution and production, so Fever-Tree receives a profit share and royalty-like income while Molson Coors funds much of the US working capital and marketing. Fever-Tree has no debt, about £91m of cash, and is buying back its own shares heavily. If the US transition works and the rest of the world keeps growing, earnings could recover strongly. The simple thesis: a strong, understandable consumer brand with a more capital-light US model, returning cash to shareholders, and priced on forward earnings that could prove too low if management hits targets.

Stock Category

Do You Understand This Business?

Yes. Fever-Tree sells premium carbonated mixers and adult soft drinks: tonic, ginger beer, ginger ale, sodas, and cocktail mixers. A normal person can go into a Tesco, Sainsbury's, or a pub and see the product, understand the price premium, and judge whether it is still winning shelf space. The edge for an individual investor is the ability to observe shelf placement, consumer trade-down, and whether the brand still feels premium. There is no complex technology. The company remains focused on its core competence, with adjacent products like ginger beer and premium soft drinks rather than unrelated 'deworsification'.

PEG Ratio Analysis

Lynch's Checklist

Tenbagger Potential

A 10x from about £901m market cap would mean a £9bn company. That is possible only if Fever-Tree becomes a truly global premium soft drink platform across the US, Europe and Asia, with the US royalty/profit-share model generating high-margin cash flow for a decade. Realistically, that is not the base case in the next few years. A successful multi-year recovery and expansion might reasonably produce a 2-4x return. I would not buy Fever-Tree solely for tenbagger potential; I would buy it for a recovery in an understandable brand with a strong balance sheet and an optional path to much bigger scale.

Key Risks

Conclusion

Lynch would appreciate the simple product, the strong net cash balance sheet, the heavy buybacks, and a story that can be explained in two minutes. The forward PEG below 0.7 is attractive if earnings recover, and the brand still has room to grow outside tonic. But Lynch would also warn against paying a 40x trailing earnings multiple for a recovery that has not yet appeared in the reported numbers. The right approach is a starter position and patience: own the brand because you can see it on shelves, but watch the September 2026 interim results for confirmation that US distribution gains are actually converting into profit and cash flow. If the recovery shows up, this is a quality low-debt consumer business with real upside; if it does not, the high trailing multiple will not protect you.

Overview

This report applies a Warren Buffett-style long-term intrinsic value lens to Fevertree Drinks plc (LSE:FEVR), focusing on business understanding, economic moat, management quality, financial strength, and intrinsic value versus the September 2026 market price of 814p.

Business Understanding

Fevertree Drinks is a simple and understandable business. It develops and sells premium carbonated mixers—primarily tonic water, ginger beer, and increasingly premium adult soft drinks—across the UK, US, Europe, and Rest of World. The brand was built on pairing quality mixers with premium spirits, but it is diversifying beyond tonic, which now represents about 45% of group revenue. This is well within a long-term consumer staples circle of competence: it sells branded, repeat-purchase beverages through retail and hospitality channels. The core economic model is easy to understand, though the recent US partnership with Molson Coors adds accounting complexity because reported revenue and margins now reflect royalty-style income rather than fully consolidated US sales.

Economic Moat Analysis

Fevertree has a narrow-to-moderate economic moat built mainly on brand intangibles and route-to-market scale. The Fever-Tree brand commands premium pricing and is the world leader in premium mixers and global ginger beer by value. Consumers and bartenders associate it with quality in the tonic and mixer category, which provides some pricing power and shelf visibility. The Molson Coors partnership adds a meaningful distribution advantage in the US, giving access to roughly 400 regional distributors and a step-change in marketing. However, unlike Coca-Cola or Brown-Forman, Fevertree does not have a wide cost or switching-cost moat. Its products are not patented, the recipe is not truly secret, and competition comes from Schweppes, Q Mixers, Fentimans, private label, and even ready-to-drink substitutes. The moat is durable while the brand remains aspirational and category-leading, but it is more vulnerable to consumer trade-down and retailer own-label pressure than a classic Buffett franchise.

Management Quality

Fevertree is founder-led, with Tim Warrillow still Chief Executive and co-founder, which supports long-term brand stewardship and authenticity. Management has been shareholder-oriented in recent years: it completed a £100m buyback in FY25, extended buybacks by another £60m across 2026, and maintained a progressive dividend. The board has also kept a debt-free balance sheet while returning cash. Transparency is generally good, including detailed adjusted revenue reconciliations after the Molson Coors deal. The main caveat is execution dependence: US growth now depends heavily on Molson Coors, and the long-term payoff from that partnership is still unproven. Overall, management quality appears capable and aligned, but the company is in the middle of a strategic transition rather than operating a proven, fully controlled growth machine.

Financial Strength

Fevertree has a strong balance sheet with about £91m of net cash, no significant bank debt, and improving working capital as US inventory and receivables transfer to Molson Coors. The rest-of-group segment improved EBITDA margin to 23.6%, demonstrating underlying profitability outside the US transition. However, group adjusted EBITDA fell 16% in FY25 to £42.4m, with margins down to 11.3%, and reported net income was about £22.6m. Cash from operations fell to £36.8m, and free cash flow after small capex is modest relative to the £901m market capitalisation. Return on equity is only around 10% on reported net income, reflecting the transition. Financially, the company is safe and liquid, but current returns do not yet resemble a high-return Buffett-style compounding machine.

Intrinsic Value Assessment

Using FY25 normalised earnings of about £29m, adding back roughly £7m of depreciation and amortisation, and subtracting about £5m of maintenance capex gives approximate owner earnings of £31m. At a market capitalisation near £901m, that is an owner-earnings yield of only about 3.4%. Enterprise value is about £810m after net cash, implying roughly 19x FY25 adjusted EBITDA. Forward EPS estimates imply a material recovery to around 39p, putting the stock on a forward P/E near 21. If the US transition works and earnings compound from here, a 22–25x forward multiple on 39p would suggest fair value around 858–975p per share. At 814p, the shares are not clearly overvalued, but they discount a meaningful recovery and offer only a modest margin of safety. A conservative long-term buyer would prefer a lower price to compensate for transition execution risk.

Key Risks

Investment Details